Premium Crisaborole API in Pakistan: Reliable Raw Material Supply for Pharmaceutical Formulators

Premium Crisaborole API in Pakistan: Reliable Raw Material Supply for Pharmaceutical Formulators

Product Name: Crisaborole (Active Pharmaceutical Ingredient)

Supplier / Distributor: Morgan

Therapeutic Category: Phosphodiesterase 4 (PDE4) Inhibitor

Indications: Atopic Dermatitis (Eczema)

Compliance Notice: This technical data page is strictly for B2B pharmaceutical manufacturers, contract manufacturing organizations (CMOs), and analytical laboratories. The Crisaborole distributed by Morgan is a highly purified Active Pharmaceutical Ingredient (API) intended exclusively for commercial formulation and laboratory R&D. It is not a finished drug product.

About Morgan: Morgan Chemicals (Pvt.) Ltd. is a pharmaceutical raw material trading and distribution company. We source APIs from DRAP-registered and internationally certified manufacturers and supply exclusively to licensed pharmaceutical companies, CMOs, and research facilities. We do not manufacture APIs or sell finished medicines.

Product Overview and Mechanism of Action

Crisaborole is a novel, boron-based small-molecule Active Pharmaceutical Ingredient (API). In dermatological pharmacology, it is classified as a non-steroidal phosphodiesterase 4 (PDE4) inhibitor. For pharmaceutical manufacturers focused on expanding their topical dermatology portfolios, this API represents a critical advancement in the management of chronic inflammatory skin conditions.

The pharmacological profile of Crisaborole is distinguished by its unique benzoxaborole chemistry. The inclusion of a boron atom allows for a low molecular weight compound that effectively penetrates the human epidermis. At the cellular level, the API functions by competitively and reversibly inhibiting the PDE4 enzyme, which is overactive in the epidermal cells of patients with atopic dermatitis.

Under normal physiological conditions, PDE4 is responsible for the degradation of cyclic adenosine monophosphate (cAMP). By blocking this enzyme, Crisaborole facilitates an increase in intracellular cAMP levels. This elevation directly suppresses the release of pro-inflammatory cytokines—such as tumor necrosis factor-alpha (TNF-α), interleukin-2 (IL-2), IL-4, and IL-31—while simultaneously promoting the production of anti-inflammatory mediators.

For pharmaceutical formulation scientists, integrating this API enables the development of highly effective, non-steroidal topical therapeutics. In commercial manufacturing, this active ingredient is standardly formulated into a 2% topical ointment.

Sourcing Crisaborole in Pakistan: Morgan’s Supply Network

Developing and commercializing advanced dermatological formulations requires a highly resilient and traceable raw material pipeline. Procuring specialty non-steroidal APIs for local commercial manufacturing frequently involves navigating extended lead times, stringent customs bottlenecks, and highly complex regulatory compliance. Sourcing Crisaborole Pakistan through Morgan’s localized distribution network mitigates these complex supply chain risks.

Morgan sources commercial-scale and pilot-scale quantities from global manufacturing partners operating in strict adherence to ICH Q7 Good Manufacturing Practice (GMP) guidelines. Partnering with Morgan as your primary supply vendor secures several operational provisions for your manufacturing facility:

• DRAP Submission Assistance: Morgan coordinates with DRAP-registered API manufacturers to obtain and forward the necessary compliance documentation on your behalf. This includes the open part of the Drug Master File (DMF), comprehensive impurity profiles, and accelerated stability data to strictly support your Drug Regulatory Authority of Pakistan (DRAP) dossier submissions.
• Supply Chain Stability: Our localized API inventory management eliminates international transit variables. Whether you require a standard batch or are scaling up a high-volume Crisaborole api Pakistan procurement order, we help ensure that your commercial batch schedules and production timelines are met without costly line stoppages or raw material shortages.
• Batch-to-Batch Uniformity: Every shipment coordinated by Morgan includes a detailed Certificate of Analysis (CoA) issued by the original manufacturer. We ensure our supplied batches maintain consistent chemical purity, controlled moisture limits, and a precise particle size distribution (PSD) for predictable behavior during compounding and emulsification processes.

Technical Specifications for QA & R&D

The Crisaborole API supplied by Morgan undergoes exacting analytical testing at the source to meet current international pharmacopeial standards.

• Chemical Name: 5-(4-cyanophenoxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaborole
• CAS Number: 906673-24-3
• Appearance: White to off-white crystalline solid powder
• Molecular Formula: C14H10BNO3
• Molecular Weight: 251.05 g/mol
• Assay / Purity (HPLC): ≥ 99.0%
• Solubility Profile: Detailed solubility parameters across standard organic solvents (such as propylene glycol and ethanol) and aqueous buffers are documented in the technical data sheet to assist your analytical R&D teams with vehicle selection and pre-formulation stability studies.

Manufacturing and Handling Guidelines for Formulators

While Crisaborole does not carry the severe teratogenic profiles of certain systemic immunosuppressants, it is a pharmacologically active compound. Facilities processing this API must enforce strict occupational exposure limits (OEL) to protect personnel on the manufacturing floor.

• Storage Conditions: Store the raw API powder in securely closed, light-resistant containers. Maintain climate-controlled conditions as specified by the batch protocol (typically controlled room temperature, strictly protected from excessive heat and ambient humidity) to prevent degradation and maintain structural integrity.
• Occupational Safety: Personnel handling the pure API powder must follow advanced industrial containment protocols. Processing requires appropriate Personal Protective Equipment (PPE), including P3/N95 industrial dust masks or respirators, chemical-resistant nitrile gloves, and full protective facility garments. Dispensing, milling, and compounding stages must be executed within localized exhaust ventilation systems or dedicated negative-pressure weighing booths to prevent the inhalation of airborne particulates and facility cross-contamination.

Distributor Disclaimer: Morgan Chemicals is a pharmaceutical raw material trading and distribution company. This API is sourced from DRAP-registered, GMP-certified manufacturing partners. Morgan Chemicals does not manufacture APIs, does not hold DRAP manufacturing registration, and does not sell finished medicines. This product is supplied exclusively to licensed pharmaceutical companies, CMOs, and research facilities in Pakistan — not for individual or consumer sale.